The addition of cytogenetic abnormalities (MYC abnormalities, t(4;14), t(14;16), +1q and/or del13q), MAPK pathway mutations and DNA repair pathway mutations may refine risk stratification of patients with SM.113, 140. The gene discussed is MYC; the disease is systemic mastocytosis.